<DOC>
	<DOCNO>NCT02175225</DOCNO>
	<brief_summary>The investigator hypothesize treatment iron chelator , Deferoxamine Mesylate , improve outcome patient brain hemorrhage . The purpose study determine whether treatment Deferoxamine Mesylate sufficient promise improve outcome pursuing large clinical trial examine effectiveness treatment intracerebral hemorrhage .</brief_summary>
	<brief_title>Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial</brief_title>
	<detailed_description>This prospective , multi-center , double-blind , randomize , placebo-controlled , phase-II clinical trial . Subjects randomize either deferoxamine mesylate ( DFO ) 32 mg/kg/day ( maximum daily dose 6000 mg/day ) , saline placebo , give IV infusion 3 consecutive day . Treatment initiate within 24 hour ICH symptom onset . Randomization control baseline imbalance associate baseline ICH score , ICH onset-to-treatment time ( OTT ) , ICH volume , baseline NIHSS score , warfarin use . All subject follow 6 month receive standard care therapy participate study . Throughout study , continue assess safety DFO . At conclusion study , proportion DFO-treated subject good clinical outcome 3 month ( define modify Rankin Scale ( mRS ) score 0-2 ) compare placebo proportion futility analysis determine futile move DFO forward Phase III efficacy evaluation .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>Age ≥ 18 ≤ 80 year The diagnosis ICH confirm brain CT scan NIHSS score ≥6 GCS &gt; 6 upon presentation The first dose study drug expect administer within 24h ICH symptom onset Functional independence prior ICH , define preICH mRS ≤1 Signed date informed consent obtain . Previous chelation therapy know hypersensitivity DFO product Known severe iron deficiency anemia ( define hemoglobin concentration &lt; 7g/dL require blood transfusion ) Abnormal renal function , define serum creatinine &gt; 2 mg/dL Planned surgical evacuation ICH prior administration study drug ( placement catheter ventricular drainage contraindication enrollment ) SUSPECTED secondary ICH relate tumour , rupture aneurysm arteriovenous malformation , hemorrhagic transformation ischemic infarct , venous sinus thrombosis Infratentorial hemorrhage Irreversibly impaired brainstem function ( bilateral fix dilate pupil extensor motor posturing ) Complete unconsciousness , define score 3 item 1a NIHSS ( Responds reflex motor autonomic effect totally unresponsive , flaccid ) Preexisting disability , define preICH mRS ≥2 Coagulopathy define elevate aPTT INR &gt; 1.3 upon presentation ; concurrent use direct thrombin inhibitor ( dabigatran ) , direct factor Xa inhibitor ( rivaroxaban apixaban ) , lowmolecularweight heparin Patients confirm aspiration , pneumonia , evident bilateral pulmonary infiltrates chest xray CT scan prior enrollment Patients significant respiratory disease chronic obstructive pulmonary disease , pulmonary fibrosis , use ( chronic intermittent ) inhale O2 home FiO2 &gt; 0.35 ( &gt; 4 L/min ) prior enrollment Sepsis ( present source infection ± lactic acidosis ) ; Systemic Inflammatory Response Syndrome ( Temp &gt; 100.4F &lt; 96.8F ; Heart rate &gt; 90 ; Respiratory rate &gt; 20 PaCo2 &lt; 32 mmHg ; WBC &gt; 12 , &lt; 4 , band &gt; 10 % ) ; shock ( SBP &lt; 90 mmHg ) presentation The presence 4 follow risk modifier ARDS prior enrollment : 1 . Tachypnea ( respiratory rate &gt; 30 ) 2 . SpO2 &lt; 95 % 3 . Obesity ( BMI &gt; 30 ) 4 . Acidosis ( pH &lt; 7.35 ) 5 . Hypoalbuminemia ( albumin &lt; 3.5 g/dL ) 6 . Concurrent use chemotherapy Taking iron supplement contain ≥ 325 mg ferrous iron , prochlorperazine Patients heart failure take &gt; 500 mg vitamin C daily Known severe hearing loss Known pregnancy , positive pregnancy test , breastfeed Positive drug screen cocaine upon presentation Patients know suspected able comply study protocol due alcoholism , drug dependency , noncompliance , live another state cause Any condition , judgement investigator , might increase risk patient Life expectancy le 90 day due comorbid condition Concurrent participation another research protocol investigation another experimental therapy Indication new DNR Comfort Measures Only ( CMO ) order implement within first 72 hour hospitalization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Brain hemorrhage</keyword>
	<keyword>Cerebral hemorrhage</keyword>
	<keyword>Bleeding brain</keyword>
	<keyword>Deferoxamine</keyword>
	<keyword>iDEF trial</keyword>
</DOC>